SCHEMBL4407745

SCHEMBL4407745

CC(=O)c1ccc2[nH]nc(Cl)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAB2 O43741 1/20 0.47
PRKAG1 P54619 1/20 0.47
PRKAA2 P54646 1/20 0.47
PRKAA1 Q13131 1/20 0.47
PRKAG3 Q9UGI9 1/20 0.47
PRKAG2 Q9UGJ0 1/20 0.47
PRKAB1 Q9Y478 1/20 0.47
KIF11 P52732 1/20 0.45
JAK2 O60674 5/20 0.44
JAK1 P23458 5/20 0.44
MAPK1 P28482 6/20 0.42
MAP2K4 P45985 4/20 0.42
MAPKAPK3 Q16644 2/20 0.42
MAPK6 Q16659 2/20 0.42
HTR1A P08908 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
SLC2A1 P11166 1/20 0.42
MAPKAPK2 P49137 1/20 0.41
MAPKAPK5 Q8IW41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8890934 0.87 PRKAB2 (0.50) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL1145032 0.85 MAP2K4 (0.50) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL29564826 0.83 MAP2K4 (0.54) KIF11JAK2JAK1MAP2K4ALDH1A1
SCHEMBL4399990 0.83 JAK2 (0.41) JAK2JAK1MAPK1MAP2K4MAPKAPK3
SCHEMBL23675227 0.83 MAP2K4 (0.54) KIF11JAK2JAK1MAP2K4ALDH1A1
SCHEMBL16308650 0.81 KIF11 (0.50) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL4404641 0.81 JAK2 (0.58) KIF11JAK2JAK1HTR1AHTR1D
SCHEMBL16125483 0.80 KIF11 (0.45) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL15479089 0.80 KIF11 (0.45) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL7979377 0.79 MAPK1 (0.50) JAK2JAK1MAPK1MAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 US disclosed
WO-2012056372-A1 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2012-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 PRKAB2 4875/4885PRKAG1 4877/4885PRKAA2 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.